PT1126870E - Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose - Google Patents

Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose

Info

Publication number
PT1126870E
PT1126870E PT99956559T PT99956559T PT1126870E PT 1126870 E PT1126870 E PT 1126870E PT 99956559 T PT99956559 T PT 99956559T PT 99956559 T PT99956559 T PT 99956559T PT 1126870 E PT1126870 E PT 1126870E
Authority
PT
Portugal
Prior art keywords
vegf
restenosis
gene
protein
prevention
Prior art date
Application number
PT99956559T
Other languages
English (en)
Portuguese (pt)
Inventor
Yla-Herttuala Seppo
Alitalo Kari
Mikko O Hiltunen
Markku M Jeltsch
Marc G Achen
Original Assignee
Licentia Ltd
Ludwig Inst Cancer Res
Seppo Yla Herttuala
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd, Ludwig Inst Cancer Res, Seppo Yla Herttuala filed Critical Licentia Ltd
Publication of PT1126870E publication Critical patent/PT1126870E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99956559T 1998-10-26 1999-10-26 Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose PT1126870E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26

Publications (1)

Publication Number Publication Date
PT1126870E true PT1126870E (pt) 2005-01-31

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99956559T PT1126870E (pt) 1998-10-26 1999-10-26 Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (https=)
JP (2) JP4769929B2 (https=)
CN (1) CN1338943A (https=)
AT (1) ATE275417T1 (https=)
AU (1) AU768330B2 (https=)
CA (1) CA2340593C (https=)
DE (1) DE69920031T2 (https=)
ES (1) ES2229788T3 (https=)
NO (1) NO20012017L (https=)
NZ (1) NZ510121A (https=)
PT (1) PT1126870E (https=)
WO (1) WO2000024412A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
ATE481097T1 (de) * 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
AU2003224587A1 (en) * 2002-04-30 2003-11-17 Fit Biotech Oyj Plc Medical device
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
WO2005039556A1 (ja) * 2003-10-29 2005-05-06 Institute Of Medicinal Molecular Design. Inc. 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
WO2005089822A1 (ja) * 2004-03-18 2005-09-29 Kensuke Egashira 薬剤・遺伝子溶出型ステント
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
CN101563102B (zh) 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
IL286675B2 (en) * 2019-03-29 2026-02-01 Abiomed Inc Systems and methods for left ventricular unloading in biological therapy or vector gene therapy
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
EP0977854A2 (en) * 1997-04-25 2000-02-09 Collateral Therapeutics Truncated vegf-related proteins

Also Published As

Publication number Publication date
EP1126870A2 (en) 2001-08-29
AU768330B2 (en) 2003-12-11
EP1126870B1 (en) 2004-09-08
NO20012017L (no) 2001-06-26
NO20012017D0 (no) 2001-04-24
JP4769929B2 (ja) 2011-09-07
JP5231587B2 (ja) 2013-07-10
AU1314700A (en) 2000-05-15
CA2340593C (en) 2012-05-08
JP2011173874A (ja) 2011-09-08
ES2229788T3 (es) 2005-04-16
CA2340593A1 (en) 2000-05-04
CN1338943A (zh) 2002-03-06
DE69920031D1 (de) 2004-10-14
WO2000024412A3 (en) 2000-08-03
JP2002528420A (ja) 2002-09-03
ATE275417T1 (de) 2004-09-15
DE69920031T2 (de) 2005-09-22
WO2000024412A2 (en) 2000-05-04
NZ510121A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
PT1126870E (pt) Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose
DE69827192D1 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DK0690872T3 (da) Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
JP2002531055A5 (https=)
ATE209686T1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
ATE163046T1 (de) Genetische veränderung von endothelzellen
PT814827E (pt) Factor de crescimento vascular endotelial-b
ATE342358T1 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
SE8902532L (sv) Bestaemning av plasmaproteiner
DE69841041D1 (de) Stent beschichtet mit dna
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
EP0960117A4 (en) ON FIBROBLASTS GROWTH FACTOR HOMOLOGICAL FACTORS (FHFs) AND METHOD OF APPLICATION
DK1169058T3 (da) Insulinlignende vækstfaktorbindingsprotein-4-protease
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb